Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, Sun Pharma Advanced Research Company has informed about submission of the Press Release titled, ’SPARC announces Top-line Results of Pivotal Bioequivalence Study for Paclitaxel Injection Concentrate for Suspension being released by the company’, which is self-explanatory.
The above information is a part of company’s filings submitted to BSE.